Literature DB >> 3157745

In vivo treatment of neonatal mice with anti-I-A antibodies interferes with the development of the class I, class II, and Mls-reactive proliferating T cell subset.

A M Kruisbeek, S Bridges, J Carmen, D L Longo, J J Mond.   

Abstract

In this study we investigated the effect of monoclonal anti-I-A Ab treatment of neonatal mice on the development of alloreactive class I-specific, class II-specific, and Mls-specific T cell proliferative responses. Responses to both class I and class II alloantigens, as well as to Mls antigens, were nearly abrogated at the end of the 2- to 3-wk in vivo treatment period in both the thymus and the spleen. Development of suppressor cells could be excluded as the cause of the observed defect. Diminished responsiveness could not be restored by the addition of IL 2-containing supernatant, suggesting that the reduced T cell proliferative response in anti-I-A-treated mice is due to defective or absent MHC-specific T cell precursors. Furthermore, generation of alloreactive class I-specific proliferative responses was dependent on self-class II recognition, thus providing an explanation for the absence of class I-specific proliferating T cells. Finally, a non-Ia-restricted T cell response, i.e., Con A-induced proliferation, was not affected by anti-I-A Ab treatment. It was previously reported that neonatal anti-Ia Ab treatment results in reduced Ia-antigen expression in the thymus, and that the development of the class I-specific CTL precursors proceeds undisturbed in these mice. The present results extend these findings and suggest that in vivo development of class II-restricted T cells is dependent on interaction with Ia-encoded products on cells either in the thymus or at other sites where T cells undergo development. Moreover, these results demonstrate that in vivo development of the alloreactive class II-specific T cell repertoire is dependent on development of self-class II recognition.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3157745

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Acquisition of MHC-restriction specificities: role of thymic stromal cells.

Authors:  A M Kruisbeek; D L Longo
Journal:  Surv Immunol Res       Date:  1985

Review 2.  Thymic selection of the T-cell repertoire.

Authors:  A M Kruisbeek; J Zúñiga-Pflücker; S Marusić-Galesić; M A Weston; L Tentori; D L Longo
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

3.  Primary polyoma virus-induced murine thymic epithelial tumors. A tumor model of thymus physiology.

Authors:  G P Hoot; J R Kettman
Journal:  Am J Pathol       Date:  1989-10       Impact factor: 4.307

4.  T cell differentiation and generation of the antigen-specific T cell repertoire in man: observations in MHC class II deficiency.

Authors:  J W Mannhalter; H M Wolf; I Hauber; M Miricka; H Gadner; M M Eibl
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

5.  An enhanced postnatal autoimmune profile in 24 week-old C57BL/6 mice developmentally exposed to TCDD.

Authors:  A Mustafa; S D Holladay; M Goff; S G Witonsky; R Kerr; C M Reilly; D P Sponenberg; R M Gogal
Journal:  Toxicol Appl Pharmacol       Date:  2008-04-30       Impact factor: 4.219

6.  Anti-CD11a prevents deletion of self-reactive T cells in neonatal C57BR mice.

Authors:  J Quddus; A Kaplan; B C Richardson
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

7.  Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells).

Authors:  M I Perez; R L Edelson; L John; L Laroche; C L Berger
Journal:  Yale J Biol Med       Date:  1989 Nov-Dec

Review 8.  Prenatal immunotoxicant exposure and postnatal autoimmune disease.

Authors:  S D Holladay
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

9.  A T cell receptor-specific blockade of positive selection.

Authors:  K K Baldwin; P A Reay; L Wu; A Farr; M M Davis
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.